As the primary mediators of cellular processes, proteins represent critical drug targets and are key to understanding the dynamic functional events that drive disease processes and therapeutic response.
These approaches provide direct protein quantitation with peptide-level readouts, enabling precise identification of proteins and their proteoforms across the breadth of the proteome.
Measuring 10,000+ protein groups in diverse FFPE tissue and tumor samples – with exceptional reproducibility, and at scale.
As new drug modalities allow for increasingly precise therapeutic targeting, the need to accurately assess protein abundance, activity, and modifications has become more critical.
Sapient’s discovery proteomics workflows are built to match the sophistication of modern therapeutics and guide mechanism‑focused drug development.
| Category | Sapient Discovery Proteomics |
|---|---|
| Proteome Coverage | Advanced extraction and enrichment processes, including specialized “capture‑and‑hold” nanoparticle chemistry for plasma, enable high‑sensitivity measurements across thousands of proteins — including the low‑abundance proteome. |
| Reproducibility | Direct, peptide‑level sequencing removes reliance on antibodies and eliminates non‑specific binding risk. Single‑fraction, single‑injection workflows deliver exceptional reproducibility (median CV <12% across matrices). |
| PTMs & Isoforms | Workflows detect splice variants, truncations, indels, missense variants, and other non‑canonical forms, as well as PTMs including phospho‑ and glyco‑proteins. |
| Throughput | Amenable to high throughput analyses across hundreds of samples per day. |
| Multi‑Omic Integration | Seamlessly integrates with Sapient’s metabolomics, lipidomics, cytokine profiling, and DNA/RNA sequencing offerings to connect upstream regulation with downstream functional outcomes. |
Directly quantify proteins and their modified forms for a more accurate readout of dynamic disease processes and drug effects.
We deliver high-specificity, reproducible measures across thousands of proteins simultaneously to maximize discovery potential and confidence in findings.
We can rapidly move biomarkers and targets identified in discovery to quantitative targeted assays, with analytical validation based on the appropriate context of use.
As the only multi-omics partner with a population-scale molecular-clinical database – Sapient’s DynamiQ Insights Engine – we can both analyze your samples and validate the findings in independent real-world cohorts.
DynamiQ can enhance and accelerate your discovery proteomics study in a number of ways, including through:
We can use our large-scale reference dataset to confirm and contextualize disease and clinical links of proteins observed in your study.
Accelerate translation of identified targets and biomarkers with cross-validation in a real-world cohort to confirm observed signals are human‑relevant.
Our DynamiQ Tumor-Tissue virtual biobank enables rapid discovery and validation of tractable, disease-modifying targets – including cell surface proteins and PTMs.
Sapient directly measures proteins and their proteoforms using advanced mass spectrometry rather than relying on RNA as a proxy or on affinity‑based assays that use antibodies for indirect protein measure. This approach delivers more accurate and reproducible protein quantification, with the ability to resolve isoforms and PTMs that other platforms often miss.
When comparing our method to traditional mass spectrometry, Sapient has made significant technological advancements across sample handling, protein extraction, mass spectrometry hardware, and software to improve throughput and sensitivity, even in sample matrices with broad dynamic range. Our workflows are proven to deliver high-precision, tightly QC’ed proteomics datasets at scale.
RNA ≠ protein. Studies have continually shown that mRNA and protein levels are often poorly correlated, because protein abundance and activity often shift independently of RNA due to post‑transcriptional regulation, alternative splicing, protein degradation, and post‑translational modifications. While RNA can predict potential protein activity, direct protein profiling reveals the true functional state of a cell or tissue.
Affinity‑based methods like Olink® and SomaScan® have proven quite powerful for discovery of new protein biomarkers and targets. These approaches, however, measure an antibody’s interaction with a target protein rather than the protein itself, which can introduce challenges such as non‑specific binding and antibody cross-reactivity. It can also be costly and time-consuming to develop antibodies that can detect protein isoforms or PTMs.
Sapient’s mass spectrometry–based workflows overcome these constraints by providing unbiased, direct protein measurements that complement affinity‑based analyses through both orthogonal validation and discovery of biomarkers not defined in pre-set panels – including PTMs and protein variants underlying disease heterogeneity or treatment response and resistance.
Our next-generation technologies significantly improve throughput to deliver this quantitative fidelity at scale, and are broadly applicable across diverse sample types – including plasma, tissues, and other biological matrices.
Yes, we can rapidly move biomarkers and targets identified through our discovery screenings – and validated as human-relevant in DynamiQ – to quantitative targeted assays with analytical validation based on appropriate context of use (COU) statements.
This ensures that your study findings are not only clinically meaningful, but clinically actionable.
If you are looking to generate discovery proteomics data without the hurdles of new sample collection, Sapient offers our DynamiQ Tumor-Tissue virtual biobank for streamlined access to archived samples, including FFPE tumors and normal tissue for differential analysis.
We can also query our DynamiQ database before any sample analysis begins, using the multi-omics data already generated to scout for potential biomarkers or test early hypotheses in virtual cohorts and build confidence in a study’s viability.
Absolutely. As a multi‑omics partner, Sapient can integrate your discovery proteomics data with metabolomics, lipidomics, cytokine, and DNA/RNA measures to build comprehensive mechanistic insight from regulation through downstream functional outcomes.
Use the form to request proteomics services. If you have questions, we encourage you to meet with our team.
"*" indicates required fields
